Skip to content

Advertisement

Articles

Page 13 of 14

  1. Content type: Review

    Recent epidemiologic studies have noted that risk factors for atherosclerosis (for example, diabetes mellitus, hypertension, and hyperlipidemia) are associated with increased risk of incident Alzheimer's disea...

    Authors: Helena C Chui, Ling Zheng, Bruce R Reed, Harry V Vinters and Wendy J Mack

    Citation: Alzheimer's Research & Therapy 2012 3:1

    Published on:

  2. Content type: Meeting report

    Although the molecular mechanisms underlying the pathogenesis of Alzheimer's disease and other related neurodegenerative diseases remain unclear, accumulation of misfolded proteins, neuroinflammation, mitochon...

    Authors: Rachel F Lane, Diana W Shineman and Howard M Fillit

    Citation: Alzheimer's Research & Therapy 2011 3:36

    Published on:

  3. Content type: Review

    Patient-reported outcome (PRO) measures are used to evaluate disease and treatments in many therapeutic areas, capturing relevant aspects of the disorder not obtainable through clinician or informant report, i...

    Authors: Lori Frank, William R Lenderking, Kellee Howard and Marc Cantillon

    Citation: Alzheimer's Research & Therapy 2011 3:35

    Published on:

  4. Content type: Commentary

    Because the pathologic processes that underlie Alzheimer's disease (AD) appear to start 10 to 20 years before symptoms develop, there is currently intense interest in developing techniques to accurately predic...

    Authors: Deborah E Barnes and Sei J Lee

    Citation: Alzheimer's Research & Therapy 2011 3:33

    Published on:

  5. Content type: Research

    With the recent publication of new criteria for the diagnosis of preclinical Alzheimer's disease (AD), there is a need for neuropsychological tools that take premorbid functioning into account in order to dete...

    Authors: Steven D Shirk, Meghan B Mitchell, Lynn W Shaughnessy, Janet C Sherman, Joseph J Locascio, Sandra Weintraub and Alireza Atri

    Citation: Alzheimer's Research & Therapy 2011 3:32

    Published on:

  6. Content type: Review

    Animal models have contributed significantly to our understanding of the underlying biological mechanisms of Alzheimer's disease (AD). As a result, over 300 interventions have been investigated and reported to...

    Authors: Diana W Shineman, Guriqbal S Basi, Jennifer L Bizon, Carol A Colton, Barry D Greenberg, Beth A Hollister, John Lincecum, Gabrielle G Leblanc, Linda (Bobbi) H Lee, Feng Luo, Dave Morgan, Iva Morse, Lorenzo M Refolo, David R Riddell, Kimberly Scearce-Levie, Patrick Sweeney…

    Citation: Alzheimer's Research & Therapy 2011 3:28

    Published on:

  7. Content type: Commentary

    Patients with mild cognitive impairment are at an increased risk of progression to Alzheimer's disease. However, not all patients with mild cognitive impairment progress, and it is difficult to accurately iden...

    Authors: Rik Ossenkoppele, Bart NM van Berckel and Niels D Prins

    Citation: Alzheimer's Research & Therapy 2011 3:26

    Published on:

  8. Content type: Research

    The Relevant Outcome Scale for Alzheimer's Disease (ROSA) is a new observer rating instrument recently developed for routine medical practice. The validity and reliability of ROSA as well as sensitivity to cha...

    Authors: Vjera A Holthoff, Steven Ferris, Ralf Ihl, Philippe Robert, Bengt Winblad, Serge Gauthier, Kati Sternberg and Frank Tennigkeit

    Citation: Alzheimer's Research & Therapy 2011 3:27

    Published on:

  9. Content type: Review

    [11C]Pittsburgh Compound B positron emission tomography has now been extensively used to evaluate the amyloid load in different types of dementia and has become a powerful research tool in the field of neurodegen...

    Authors: Paul Edison, Rainer Hinz and David J Brooks

    Citation: Alzheimer's Research & Therapy 2011 3:25

    Published on:

  10. Content type: Review

    Alzheimer's disease (AD) therapies are increasingly being tested in global clinical trials. A search of ClincalTrials.gov revealed that of 269 currently active trials, 28% are currently being conducted in the ...

    Authors: Jeffrey Cummings, Robert Reynders and Kate Zhong

    Citation: Alzheimer's Research & Therapy 2011 3:24

    Published on:

  11. Content type: Research

    The objective of this study was to describe the longitudinal cognitive outcome in Alzheimer's disease (AD) and analyze factors that affect the outcome, including the impact of different cholinesterase inhibito...

    Authors: Carina Wattmo, Åsa K Wallin, Elisabet Londos and Lennart Minthon

    Citation: Alzheimer's Research & Therapy 2011 3:23

    Published on:

  12. Content type: Research

    Progressive language impairment is among the primary components of cognitive decline in Alzheimer's disease (AD). Because expressive and receptive language help to maintain emotional connections to caregivers ...

    Authors: Steven H Ferris, Frederick A Schmitt, Judith Saxton, Sharon Richardson, Joan Mackell, Yijun Sun and Yikang Xu

    Citation: Alzheimer's Research & Therapy 2011 3:22

    Published on:

  13. Content type: Review

    The pathology of Alzheimer's disease (AD) is characterized by amyloid plaques (aggregates of amyloid-β (Aβ)) and neurofibrillary tangles (aggregates of tau) and is accompanied by mitochondrial dysfunction, but...

    Authors: Anne Eckert, Karen Schmitt and Jürgen Götz

    Citation: Alzheimer's Research & Therapy 2011 3:15

    Published on:

  14. Content type: Research

    Neuroinflammation is thought to be important in Alzheimer's disease pathogenesis. Mast cells are a key component of the inflammatory network and participate in the regulation of the blood-brain barrier's perme...

    Authors: François Piette, Joël Belmin, Hélène Vincent, Nicolas Schmidt, Sylvie Pariel, Marc Verny, Caroline Marquis, Jean Mely, Laurence Hugonot-Diener, Jean-Pierre Kinet, Patrice Dubreuil, Alain Moussy and Olivier Hermine

    Citation: Alzheimer's Research & Therapy 2011 3:16

    Published on:

  15. Content type: Review

    The clinical and scientific study of dementia in adults with Down syndrome led to the development of the amyloid hypothesis as a fundamental concept in Alzheimer's disease pathogenesis. The journey started wit...

    Authors: Robyn A Wallace and Arthur J Dalton

    Citation: Alzheimer's Research & Therapy 2011 3:13

    Published on:

  16. Content type: Research

    APOE is the strongest risk gene for sporadic Alzheimer's disease (AD) so far. Recent genome wide association studies found links for sporadic AD with CLU and CR1 involved in Aβ clearance, and PICALM affecting int...

    Authors: Eloise H Kok, Teemu Luoto, Satu Haikonen, Sirkka Goebeler, Hannu Haapasalo and Pekka J Karhunen

    Citation: Alzheimer's Research & Therapy 2011 3:12

    Published on:

  17. Content type: Review

    Current theory suggests that β-amyloid accumulation may be an early step in the cascade that leads to cognitive impairment in Alzheimer's disease. β-Amyloid targeted positron emission tomography (PET) imaging ...

    Authors: Michael J Pontecorvo and Mark A Mintun

    Citation: Alzheimer's Research & Therapy 2011 3:11

    Published on:

  18. Content type: Research

    Novel compounds with potential to attenuate or stop the progression of Alzheimer's disease (AD) from its presymptomatic stage to dementia are being tested in man. The study design commonly used is the long-ter...

    Authors: René Spiegel, Manfred Berres, André R Miserez and Andreas U Monsch

    Citation: Alzheimer's Research & Therapy 2011 3:9

    Published on:

  19. Content type: Research

    Alzheimer's disease (AD) is widely recognized as a serious public health problem and heavy financial burden. Currently, there is no treatment that can delay or stop the progressive brain damage in AD. Recently...

    Authors: Bin Li, Maria E Gonzalez-Toledo, Chun-Shu Piao, Allen Gu, Roger E Kelley and Li-Ru Zhao

    Citation: Alzheimer's Research & Therapy 2011 3:8

    Published on:

  20. Content type: Review

    There are more than 36 million people in the US over the age of 65, and all of them are impacted by the cognitive decline and brain atrophy associated with normal aging and dementia-causing conditions like Alz...

    Authors: Neill R Graff-Radford

    Citation: Alzheimer's Research & Therapy 2011 3:6

    Published on:

  21. Content type: Research

    Levels of cerebrospinal fluid (CSF) β-amyloid (Aβ) and Tau proteins change in Alzheimer's disease (AD). We tested if the relationships of these biomarkers with cognitive impairment are linear or non-linear.

    Authors: Jonathan H Williams, Gordon K Wilcock, Jeffrey Seeburger, Aimee Dallob, Omar Laterza, William Potter and A David Smith

    Citation: Alzheimer's Research & Therapy 2011 3:5

    Published on:

  22. Content type: Review

    Alzheimer disease (AD) is a devastating neurodegenerative disease affecting 1 in 68 in the population. An arbitrary cutoff 65 years as the age of onset to distinguish between early- and late-onset AD has been ...

    Authors: Kinga Szigeti and Rachelle S Doody

    Citation: Alzheimer's Research & Therapy 2011 3:4

    Published on:

  23. Content type: Review

    Autosomal-dominant Alzheimer's disease has provided significant understanding of the pathophysiology of Alzheimer's disease. The present review summarizes clinical, pathological, imaging, biochemical, and mole...

    Authors: Randall J Bateman, Paul S Aisen, Bart De Strooper, Nick C Fox, Cynthia A Lemere, John M Ringman, Stephen Salloway, Reisa A Sperling, Manfred Windisch and Chengjie Xiong

    Citation: Alzheimer's Research & Therapy 2011 3:1

    Published on:

  24. Content type: Research

    Inhibition of gamma-secretase presents a direct target for lowering Aβ production in the brain as a therapy for Alzheimer's disease (AD). However, gamma-secretase is known to process multiple substrates in add...

    Authors: Guriqbal S Basi, Susanna Hemphill, Elizabeth F Brigham, Anna Liao, Danielle L Aubele, Jeanne Baker, Robin Barbour, Michael Bova, Xiao-Hua Chen, Michael S Dappen, Tovah Eichenbaum, Erich Goldbach, Jon Hawkinson, Rose Lawler-Herbold, Kang Hu, Terence Hui…

    Citation: Alzheimer's Research & Therapy 2010 2:36

    Published on:

  25. Content type: Meeting report

    While Alzheimer's disease researchers continue to debate the underlying cause(s) of the disease, most agree that a diverse, multi-target approach to treatment will be necessary. To this end, the Alzheimer's Dr...

    Authors: Linda H Lee, Diana W Shineman and Howard M Fillit

    Citation: Alzheimer's Research & Therapy 2010 2:33

    Published on:

  26. Content type: Review

    In a slowly progressive disorder like Alzheimer disease, evaluation of the clinical effect of novel drug candidates requires large numbers of patients and extended treatment periods. Current cell- and animal-b...

    Authors: Henrik Zetterberg, Niklas Mattsson, Kaj Blennow and Bob Olsson

    Citation: Alzheimer's Research & Therapy 2010 2:32

    Published on:

  27. Content type: Research

    There is a great need for quick tests that identify treatment response in Alzheimer's disease (AD) to determine who benefits from the treatment. In this study, A Quick Test of cognitive speed (AQT) was compare...

    Authors: Sebastian Palmqvist, Lennart Minthon, Carina Wattmo, Elisabet Londos and Oskar Hansson

    Citation: Alzheimer's Research & Therapy 2010 2:29

    Published on:

  28. Content type: Review

    With the advent of advances in biomarker detection and neuropsychological measurement, prospects have improved for identifying and tracking the progression of Alzheimer's disease (AD) from its earliest stages ...

    Authors: Larry G Brooks and David A Loewenstein

    Citation: Alzheimer's Research & Therapy 2010 2:28

    Published on:

  29. Content type: Commentary

    Structural brain deficits have been repeatedly linked to body mass index and obesity, which itself is controlled by the effects of a number of independent genetic loci. One of the most consistently replicated ...

    Authors: Lars Bertram and Hauke Heekeren

    Citation: Alzheimers Res Ther 2010 2:27

    Published on:

  30. Content type: Commentary

    Dimebon (latrepirdine) has received widespread publicity as a potential therapy for Alzheimer's disease following a very positive phase 2 study carried out in Russia and published in the Lancet in 2008. In this s...

    Authors: Roy W Jones

    Citation: Alzheimer's Research & Therapy 2010 2:25

    Published on:

  31. Content type: Review

    Atrophy measured on structural magnetic resonance imaging (sMRI) is a powerful biomarker of the stage and intensity of the neurodegenerative aspect of Alzheimer's disease (AD) pathology. In this review, we wil...

    Authors: Prashanthi Vemuri and Clifford R Jack Jr

    Citation: Alzheimer's Research & Therapy 2010 2:23

    Published on:

  32. Content type: Research

    The present review of Alzheimer's disease (AD) rating scales aims to outline the need for a new rating scale to be used in routine clinical practice for long-term medical care of AD patients. An ideal scale would...

    Authors: Philippe Robert, Steven Ferris, Serge Gauthier, Ralf Ihl, Bengt Winblad and Frank Tennigkeit

    Citation: Alzheimer's Research & Therapy 2010 2:24

    Published on: